Serial entrepreneurs, scientists and business leaders committed to innovation

John A. Dawson, CBE, is a highly experienced and globally respected figure in the healthcare sector. Most recently, he was Chief Executive Officer of Oxford Biomedica where, during his 13-year tenure, the business grew into a global market leader in viral vector technologies for cell and gene therapy, and delivered multiple high value partnerships. The company successfully manufactured the life-saving Oxford / AstraZeneca COVID-19 vaccine in early 2021.

Todd C. Davis is Ligand Pharmaceutical’s Chief Executive Officer, a position he has held since December 2022, and has served as a member of the Board since March 2007. From 2006 until 2018, Mr. Davis was a Founder and Managing Partner of HealthCare Royalty Partners, a global healthcare investment firm which grew from zero to approximately $4 billion in capital commitments during his tenure.

Susan Dexter is Chief Technical Officer / CMC Supply Chain and Non-Clinical Lead at Sonnet BioTherapeutics, Inc., managing all activities related to cell line development, process development and cGMP manufacturing, non-clinical studies and clinical supply chain. She has over thirty-five years of experience in biotechnology sciences and business development including drug development and in the CDMO arena for biological products.

David Enloe brings nearly three decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing. David is currently President and CEO of Societal CDMO, a company with a focus on novel formulation development and clinical through commercial scale manufacturing of pharmaceutical products.

Farzin Farzaneh, PhD, FRCPath, FRSB, is Chief Scientific Officer of ViroCell Biologics and serves as a member of the Board of Directors. He is also Chair of Molecular Medicine at King’s College London and Trans-campus Professor of Molecular Medicine at Technical University of Dresden, Germany.

John W. Hadden II is Chief Executive Officer and co-founder of ViroCell Biologics. A successful serial entrepreneur, John’s passion for science and medicine and business acumen have enabled him to meet the challenges of the journey from laboratory to clinic to marketing authorization with a range of life science companies. In addition to his board membership with ViroCell Biologics, John has substantial board and governance experience with for-profit companies, as well as non-profit organizations.  

Cédriane has 30+ years’ experience in venture capital, private equity and corporate finance across the US, Europe, Russia and Central Asia. She founded Disruptive Capital in 2010 alongside Edmund Truell who has an investment track record of 29% IRR over 30 years, investing across sectors including med tech, infrastructure, renewable energy and fintech. This investment record is primarily based on founding companies in-house (off market). Cédriane’s speciality is growing companies from an early stage.